Phase Zero: "Open for Business"
This article was originally published in RPM Report
Executive Summary
Despite a setback presented by a small micro-dosing trial in the UK, FDA says its "Phase Zero" program has appropriate safeguards in place and should be pursued by biopharmaceutical companies.
You may also be interested in...
Reinventing Clinical Trials
The clincal trial process needs to be modernized for the good of drug development.
A Look Back at 2006: The Pipeline Challenge
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
A Look Back at 2006: The Pipeline Challenge
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.